Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
1833-A IDENTIFYING THE POPULATION AT RISK OF HCC IN NON-ACLD CHRONIC HEPATITIS C PATIENTS CURED BY DIRECT-ACTING AGENTS: A STRATEGIC APPROACH Yen-Chun Liu 1,2 , Ya-Ting Cheng 1,2 , Yi-Cheng Chen 1,2 , Rachel Wen-Juei Jeng 1,2 , Chun-Yen Lin 1,2 , Rong-Nan Chien 1,2 , Dar-In Tai 1,2 , I-Shyan Sheen 1,2 and Yi-Chung Hsieh 1,2 , (1)Chang Gung Memorial Hospital, Linkou Branch, Taiwan, (2)College of Medicine, Chang Gung University, Taiwan Background: HCC surveillance is recommended for chronic hepatitis C (CHC) patients with advanced fibrosis (F3) or cirrhosis (F4) after successful viral eradication, according to clinical guidelines
The reviewers and contributors are identified to provide clear authorship and accountability
Local injection site reactions are relatively common with Wegovy
403,408 Overexpression of EZH2, a histone methyltransferase, is a major reason for the increased genomic distribution of H3K27me3 in metastatic PCa
If not, they should be cautious
US$ 28.81
US$ 25.89
US$ 20.27
US$ 24.69
US$ 20.17
US$ 23.67
US$ 28.17
US$ 22.34
